Nippon Kayaku Kabushiki Kaisha

Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai

Yamasa Shoyu Kabushiki Kaisha

Takashi Terada

Minoru Aoki

Hiroshi Ninomiya

Hiroshi Ohtaki

Minoru Nakada

Hamao Umezawa

Masaru Suzuki

Masaaki Ishizuka

Tetsushi Saino

Manami Morozumi

Terukatsu Sakurai

Fumihiro Sato

Tochiro Tatee

Takashi Takahira

Yuichi Yazawa

Giichi Izumi

Yasuhiko Furuta

Eiichiro Akito

Koichi Yoshida

Makoto Hosono

Mitsuharu Shiozaki

Junpei Itoh

Osamu Ishizuka

Akira Fujita

Michiko Sakai

Wataru Tanaka

Nobuharu Fukui

Masayuki Iwasaki

Gen'ichi Izu

Minoru Nakada, Deceased

Yoshiyasu Henmi

Hideyuki Ishimado

Gen'iti Idzu

The present invention relates to novel pharmaceutical use of forskolin derivatives represented by the general formula: ##STR1## wherein R.sup.1, R.sup.2 and Ac are as defined later ##STR2## (wherein R.sup.3 and R.sup.4 are each hydrogen or lower alkyl group, or R.sup.3 and R.sup.4 may be combined to represent lower alkylene group which may have oxygen or nitrogen atom in the linking chain, and n is an integer of 1 to 5); R.sup.2 represents hydrocarbon group having 2 to 3 carbon atoms; and Ac represents acetyl group. The above-mentioned forskolin derivative or a physiologically acceptable salt thereof can be used as a platelet aggregation inhibiting or controlling agent, spasmolytic agent, therapeutic agent for skin ulcer, peripheral circulation improving agent for limbs and differentiation inducing and promoting agent.

Pharmaceutical use of forskolin derivatives

This invention relates to an etoposide preparation containing an etoposide composition comprising an etoposide, polyvinylpyrrolidone, and water-soluble cellulose ether derivative wherein the proportion of the respective components is about 0.25 to 2 parts by weight for polyvinylpyrrolidone and about 0.0028 to 0.2 parts by weight for the water-soluble cellulose ether derivative per 1 part by weight of the etoposide, and about 10 to 20% (w/w) for the etoposide in the whole amount of the composition.

Etoposide preparations

The present invention relates to hard capsules of cytarabine ocfosfate which is useful as an anti-leukemia drug applicable to oral administration. By providing the cytarabine ocfosfate hard capsule comprising (1) cytarabine ocfosfate, (2) a high molecular compound functioning as a disintegrator and (3) an alkali, there can be provided pharmaceutical preparations having excellent disintegration property and stability. The cytarabine ocfosfate hard capsules are applicable to clinical use.

Cytarabine ocfosfate hard capsule

Disclosed herein are a novel process for producing 1-.beta.-D-arabinofuranosylcytosine-5'-stearylphosphate monosodium salt, which has been expected as an oral antitumor agent, and 1-.beta.-D-arabinofranosylcytosine-5'-stearylphosphate monosodium salt monohydrate obtained from the above-mentioned monosodium salt.

Process for producing

A stable, non-hygroscopic, crystalline .gamma.-form of bestatin is prepared from the .alpha.- or .beta.-form of bestatin by heating at a temperature of from about 148.degree. C. to the melting point of bestatin, or by suspending or kneading in certan specified solvents.

Crystalline upsilon-form bestatin and processes for its preparation

A stable, non-hygroscopic, crystalline .gamma.-form of bestatin is prepared from the .alpha.- or .beta.-form of bestatin by heating at a temperature of from about 148.degree. C. to the melting point of bestatin, or by suspending or kneading in certain specified solvents.

Crystalline gamma-form bestatin and processes for its preparation

This invention relates to etoposide solution preparations, which exhibit excellent absorbability in vivo, comprising a container and, enclosed therein, an etoposide solution composition containing etoposide and a water-soluble cellulose derivative or polyvinylpyrrolidone.

Etoposide soft capsules comprising soft gelatin shells of pH 3.7 to 5.7 and, enclosed therein, an etoposide solution containing an organic acid.

Etoposide soft capsules

The present invention relates to a process for producing polyacrylic acid salt granules easily soluble in water characterized in that a water-soluble powder of polyacrylic acid salt is granulated according to fluidized bed granulation method while an aqueous solution of the polyacrylic acid salt of a viscosity of 50-700 c.p.s. is sprayed thereon.

Process for producing polyacrylic acid salt granules easily soluble in

A pharmaceutical preparation of oral cavity administration, characterized by being a mixture of a pharmacologically active agent, a pharmaceutical carrier, and sodium polyacrylate, in conventional dosage form. It has advantages in that it adheres strongly to local site and dissolves gradually over a prolonged period of time while releasing appropriate amounts of the active agent.

Pharmaceutical preparation for oral cavity administration

Growing community of inventors

Yono, Japan

Takashi Terada